Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients
Shigetaka Suekane(Kurume University), Masanori Noguchi(Kurume University), Uhi Toh(Kurume University), Shigeki Shichijo, Shigeru Yutani(Kurume University), Shinjiro Sakamoto(Kurume University), Koichi Yoshiyama(Kurume University), Nobukazu Komatsu(Kurume University), Shinzo Takamori(Kurume University), Satoko Matsueda(Kurume University), Mizuhiko Terasaki(Miyoshi Kasei (Japan)), Shunichi Sugawara(Sendai Kousei Hospital), Takashi Mine(Nagasaki Medical Center), Kouichiro Kawano(Kurume University), Teppei Yamada(Harvard University), Kyogo Itoh(Kurume University), Tetsuro Sasada(Kanagawa Prefectural Hospital Organization), Masayasu Naito(Kurume University), Akira Yamada(Fujita Health University)
Cited by 6
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695